- Home
- TXMD vs NXTC Comparison
TXMD vs NXTC Comparison
Compare TXMD & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- NXTC
- Stock Information
- Founded
- TXMD 2008
- NXTC 2015
- Country
- TXMD United States
- NXTC United States
- Employees
- TXMD N/A
- NXTC N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- NXTC Health Care
- Exchange
- TXMD Nasdaq
- NXTC Nasdaq
- Market Cap
- TXMD 12.7M
- NXTC 13.0M
- IPO Year
- TXMD N/A
- NXTC 2019
- Fundamental
- Price
- TXMD $1.06
- NXTC $5.55
- Analyst Decision
- TXMD
- NXTC Strong Buy
- Analyst Count
- TXMD 0
- NXTC 2
- Target Price
- TXMD N/A
- NXTC $25.50
- AVG Volume (30 Days)
- TXMD 17.5K
- NXTC 13.3K
- Earning Date
- TXMD 11-11-2025
- NXTC 11-06-2025
- Dividend Yield
- TXMD N/A
- NXTC N/A
- EPS Growth
- TXMD N/A
- NXTC N/A
- EPS
- TXMD N/A
- NXTC N/A
- Revenue
- TXMD $2,559,000.00
- NXTC N/A
- Revenue This Year
- TXMD $427.09
- NXTC N/A
- Revenue Next Year
- TXMD N/A
- NXTC N/A
- P/E Ratio
- TXMD N/A
- NXTC N/A
- Revenue Growth
- TXMD 156.93
- NXTC N/A
- 52 Week Low
- TXMD $0.70
- NXTC $2.69
- 52 Week High
- TXMD $2.44
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- TXMD 40.43
- NXTC 59.97
- Support Level
- TXMD $1.06
- NXTC $5.19
- Resistance Level
- TXMD $1.14
- NXTC $5.90
- Average True Range (ATR)
- TXMD 0.05
- NXTC 0.28
- MACD
- TXMD -0.00
- NXTC 0.07
- Stochastic Oscillator
- TXMD 5.26
- NXTC 69.03
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.